umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study
Umeå universitet, Medicinska fakulteten, Institutionen för kirurgisk och perioperativ vetenskap, Urologi och andrologi.ORCID-id: 0000-0003-2061-5769
Umeå universitet, Medicinska fakulteten, Institutionen för kirurgisk och perioperativ vetenskap, Urologi och andrologi. Department of Urology, Ryhov Hospital, J€onk€oping, Sweden.
Visa övriga samt affilieringar
2016 (Engelska)Ingår i: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, nr 5, s. 338-345Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective: The aim of this study was to assess the risk of serious adverse effects after radiotherapy (RT) with curative intention and radical prostatectomy (RP).

Materials and methods: Men who were diagnosed with prostate cancer between 1997 and 2012 and underwent curative treatment were selected from the Prostate Cancer data Base Sweden. For each included man, five prostate cancer-free controls, matched for birth year and county of residency, were randomly selected. In total, 12,534 men underwent RT, 24,886 underwent RP and 186,624 were controls. Adverse effects were defined according to surgical and diagnostic codes in the National Patient Registry. The relative risk (RR) of adverse effects up to 12 years after treatment was compared to controls and the risk was subsequently compared between RT and RP in multivariable analyses.

Results: Men with intermediate- and localized high-risk cancer who underwent curative treatment had an increased risk of adverse effects during the full study period compared to controls: the RR of undergoing a procedures after RT was 2.64 [95% confidence interval (CI) 2.56–2.73] and after RP 2.05 (95% CI 2.00–2.10). The risk remained elevated 10–12 years after treatment. For all risk categories of prostate cancer, the risk of surgical procedures for urinary incontinence was higher after RP (RR 23.64, 95% CI 11.71–47.74), whereas risk of other procedures on the lower urinary tract and gastrointestinal tract or abdominal wall was higher after RT (RR 1.67, 95% CI 1.44–1.94, and RR 1.86, 95% CI 1.70–2.02, respectively).

Conclusion: The risk of serious adverse effects after curative treatment for prostate cancer remained significantly elevated up to 12 years after treatment.

Ort, förlag, år, upplaga, sidor
2016. Vol. 50, nr 5, s. 338-345
Nyckelord [en]
Adverse effects, prostate cancer, radical prostatectomy, radiotherapy
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-127955DOI: 10.1080/21681805.2016.1194460ISI: 000384068000003PubMedID: 27333148OAI: oai:DiVA.org:umu-127955DiVA, id: diva2:1057131
Tillgänglig från: 2016-12-16 Skapad: 2016-11-21 Senast uppdaterad: 2018-06-09Bibliografiskt granskad
Ingår i avhandling
1. Adverse effects of curative treatment of prostate cancer
Öppna denna publikation i ny flik eller fönster >>Adverse effects of curative treatment of prostate cancer
2016 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Background Screening for prostate cancer is debated, there is conflicting data on the net benefit of screening. Men who consider screening need to be informed on the pros and cons. Rehospitalization after surgery can be used as an indicator of general quality of care. For radical prostatectomy, little is known on the readmission rate after surgery. Men diagnosed with low- and intermediate-risk prostate cancer have low prostate-cancer specific mortality. However, adverse effects after curative treatment can be severe and decrease quality of life. Curative treatments for prostate cancer differ mainly in the pattern of adverse effects but detailed analysis of long-term adverse effects is lacking.

The aim of this thesis was to assess the perioperative quality of radical prostatectomy and the risk of adverse effects after curative treatment for prostate cancer.

Material and Methods In this thesis, data from the National Prostate Cancer Register (NPCR) and other nationwide Swedish registers were used. By use of the Swedish personal identity number, NPCR was cross-linked to other registers creating Prostate Cancer data Base Sweden (PCBaSe), a large dataset for research.

Results The proportion of men who had received information on the pros and cons of screening for prostate cancer with PSA testing was low (14%) indicating that the majority of men who were screened did not make an informed decision. The risk of rehospitalization within 90 days after radical prostatectomy was approximately 10% and similar after retropubic and robot-assisted radical prostatectomy. Compared to controls, there was an increased risk of adverse effects after both radiotherapy and radical prostatectomy up to twelve years after treatment and the overall risk was quite similar after retropubic and robot-assisted radical prostatectomy.

Conclusion Improved information to men on the pros and cons of PSA screening is warranted. The risk of adverse effects was elevated up to 12 years after curative treatment for prostate cancer. The pattern of adverse effects was different after radiotherapy and radical prostatectomy but quite similar after retropubic and robot-assisted radical prostatectomy.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå universitet, 2016. s. 74
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1846
Nyckelord
Prostate cancer, prostate-specific antigen, decision aids, radical prostatectomy, radiotherapy, patient readmission, adverse effects
Nationell ämneskategori
Klinisk medicin
Forskningsämne
kirurgi, särskilt urologi
Identifikatorer
urn:nbn:se:umu:diva-128709 (URN)978-91-7601-559-9 (ISBN)
Disputation
2017-01-19, Hörsal E04 Farmakologihuset, Norrlands universitetssjukhus, Umeå, 09:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2016-12-21 Skapad: 2016-12-13 Senast uppdaterad: 2018-06-09Bibliografiskt granskad

Open Access i DiVA

fulltext(2086 kB)135 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 2086 kBChecksumma SHA-512
e7dbe9a0fd065074097142a8571a65b304626b81e76b34fa47ccbeef5ad5f5866e380583aa13dc78a5c1ac57f13920ad68854ddd0d5134fb784127f4ae78f7aa
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Fridriksson, Jón O.Robinson, DavidWidmark, AndersKarlsson, Camilla T.Stattin, Pär

Sök vidare i DiVA

Av författaren/redaktören
Fridriksson, Jón O.Robinson, DavidWidmark, AndersKarlsson, Camilla T.Stattin, Pär
Av organisationen
Urologi och andrologiOnkologi
I samma tidskrift
Scandinavian journal of urology
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 135 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 700 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf